Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Multiorgan Imaging for Interorgan Crosstalk in Cardiometabolic Diseases.

  • Devesa, Ana
  • Delgado, Victoria
  • Valkovic, Ladislav
  • Lima, Joao A C
  • Nagel, Eike
  • Ibanez, Borja
  • Raman, Betty
Cardiometabolic diseases encompass a group of conditions characterized by metabolic and inflammatory abnormalities that increase the risk of diabetes and cardiovascular disease. These syndromes involve multiple organs, including the heart, arterial system, brain, skeletal muscle, adipose tissue, hematopoietic system, liver, kidneys, and pancreas. The crosstalk between these organs contributes to the development of disease. Advances in imaging techniques, such as magnetic resonance imaging, magnetic resonance spectroscopy, computed tomography, and positron emission tomography, have revolutionized the evaluation of these conditions. Hybrid imaging modalities, such as positron emission tomography/computed tomography and positron emission tomography/magnetic resonance imaging, provide unique insights into the anatomy and metabolic alterations occurring in response to cardiometabolic risk factors. These methods are particularly valuable for assessing multisystemic involvement and interorgan crosstalk, revealing critical interactions such as the brain-heart axis, the heart-liver axis, and the fat-muscle-heart dynamics. This review discusses the role of state-of-the-art imaging techniques in evaluating the pathophysiological mechanisms underlying these complex syndromes and the clinical applications of the different imaging techniques in the assessment of cardiometabolic diseases.
Repisalud
Publication Artículo científico (JournalArticle)

Controlled Drug Release Systems for Cerebrovascular Diseases

  • Celia Martín‐Morales
  • Sofia Caspani
  • Manuel Desco
  • Célia Tavares de Sousa
  • María Victoria Gómez‐Gaviro
This review offers a comprehensive exploration of optimized drug delivery systems tailored for controlled release and their crucial role in addressing cerebrovascular diseases. Through an in-depth analysis, various controlled release methods, including nanoparticles, liposomes, hydrogels, and other emerging technologies are examined. Highlighting the importance of precise drug targeting, it is delved into the underlying mechanisms of these delivery systems and their potential to improve therapeutic outcomes while minimizing adverse effects. Additionally, the specific applications of these optimized drug delivery systems in treating cerebrovascular disorders such as ischemic stroke, cerebral aneurysms, and intracranial hemorrhage are discussed. By shedding light on the advancements in drug delivery techniques and their implications in cerebrovascular medicine, this review offers valuable insights into the future of therapeutic interventions in neurology.
Repisalud
Publication Artículo científico (JournalArticle)

Influence of Subclinical Atherosclerosis Burden and Progression on Mortality.

  • Fuster, Valentin
  • García-Álvarez, Ana
  • Devesa, Ana
  • Mass, Virginia
  • Owen, Ruth
  • Quesada, Antonio
  • Fuster, José J
  • García-Lunar, Inés
  • Pocock, Stuart
  • Sánchez-González, Javier
  • Sartori, Samantha
  • Peyra, Carlos
  • Andres, Vicente
  • Muntendam, Pieter
  • Ibanez, Borja
Atherosclerosis is a dynamic process. There is little evidence regarding whether quantification of atherosclerosis extent and progression, particularly in the carotid artery, in asymptomatic individuals predicts all-cause mortality. This study sought to evaluate the independent predictive value (beyond cardiovascular risk factors) of subclinical atherosclerosis burden and progression and all-cause mortality. A population of 5,716 asymptomatic U.S. adults (mean age 68.9 years, 56.7% female) enrolled between 2008 and 2009 in the BioImage (A Clinical Study of Burden of Atherosclerotic Disease in an At Risk Population) study underwent examination by vascular ultrasound to quantify carotid plaque burden (cPB) (the sum of right and left carotid plaque areas) and by computed tomography for coronary artery calcium (CAC). Follow-up carotid vascular ultrasound was performed on 732 participants a median of 8.9 years after the baseline exam. All participants were followed up for all-cause mortality, the primary outcome. Trend HRs are the per-tertile increase in each variable. Over a median 12.4 years' follow-up, 901 (16%) participants died. After adjustment for cardiovascular risk factors and background medication, baseline cPB and CAC score were both significantly associated with all-cause mortality (fully adjusted trend HR: 1.23; 95% CI: 1.16-1.32; and HR: 1.15; 95% CI: 1.08-1.23), respectively (both P < 0.001), thus providing additional prognostic value. cPB performed better than CAC score. In participants with a second vascular ultrasound evaluation, median cPB progressed from 29.2 to 91.3 mm. cPB progression was significantly associated with all-cause mortality after adjusting for cardiovascular risk factors and baseline cPB (HR: 1.03; 95% CI: 1.01-1.04 per absolute 10-mm change; P = 0.01). Subclinical atherosclerosis burden (cPB and CAC) in asymptomatic individuals was independently associated with all-cause mortality. Moreover, atherosclerosis progression was independently associated with all-cause mortality.
Repisalud
Publication Artículo de revisión (ReviewArticle)

Unidirectional association of clonal hematopoiesis with atherosclerosis development.

  • Díez-Díez, Miriam
  • Ramos-Neble, Beatriz L
  • de la Barrera, Jorge
  • Silla-Castro, J C
  • Quintas, Ana
  • Vázquez, Enrique
  • Rey-Martín, M Ascensión
  • Izzi, Benedetta
  • Sánchez-García, Lucía
  • García-Lunar, Inés
  • Mendieta, Guiomar
  • Mass, Virginia
  • Gómez-López, Nuria
  • Espadas, Cristina
  • González, Gema
  • Quesada, Antonio J
  • García-Álvarez, Ana
  • Fernández-Ortiz, Antonio
  • Lara-Pezzi, Enrique
  • Dopazo, Ana
  • Sánchez-Cabo, Fátima
  • Ibáñez, Borja
  • Andrés, Vicente
  • Fuster, Valentín
  • Fuster, José J
Clonal hematopoiesis, a condition in which acquired somatic mutations in hematopoietic stem cells lead to the outgrowth of a mutant hematopoietic clone, is associated with a higher risk of hematological cancer and a growing list of nonhematological disorders, most notably atherosclerosis and associated cardiovascular disease. However, whether accelerated atherosclerosis is a cause or a consequence of clonal hematopoiesis remains a matter of debate. Some studies support a direct contribution of certain clonal hematopoiesis-related mutations to atherosclerosis via exacerbation of inflammatory responses, whereas others suggest that clonal hematopoiesis is a symptom rather than a cause of atherosclerosis, as atherosclerosis or related traits may accelerate the expansion of mutant hematopoietic clones. Here we combine high-sensitivity DNA sequencing in blood and noninvasive vascular imaging to investigate the interplay between clonal hematopoiesis and atherosclerosis in a longitudinal cohort of healthy middle-aged individuals. We found that the presence of a clonal hematopoiesis-related mutation confers an increased risk of developing de novo femoral atherosclerosis over a 6-year period, whereas neither the presence nor the extent of atherosclerosis affects mutant cell expansion during this timeframe. These findings indicate that clonal hematopoiesis unidirectionally promotes atherosclerosis, which should help translate the growing understanding of this condition into strategies for the prevention of atherosclerotic cardiovascular disease in individuals exhibiting clonal hematopoiesis.
Repisalud
Publication Artículo científico (JournalArticle)

Remote ischemic conditioning protects against anthracycline cardiotoxicity without impairing its antitumor activity.

  • Díaz-Guerra, Anabel
  • Clemente-Moragón, Agustín
  • Pollán, Ángela
  • López-Palomar, Lucía
  • Cádiz, Laura
  • Ibáñez, Borja
Anthracyclines remain a cornerstone of treatment for many cancer types; however, their cardiotoxic potential leads to cardiac dysfunction in a substantial proportion of patients, ultimately compromising long-term quality of life. Few strategies have proven effective in preventing anthracycline-induced cardiotoxicity (AIC). Among them, remote ischemic conditioning (RIC) has emerged as one of the most promising, having shown robust cardioprotective potential in preclinical studies and currently being evaluated in clinical trials. However, it remains unclear whether this intervention, while protecting the heart, could also inadvertently protect tumors from the cytotoxic effects of anthracyclines, thereby reducing their antitumor efficacy. In this study, we investigated whether RIC protects against AIC in a tumor-bearing mouse model, allowing simultaneous assessment of both cardiac and tumoral responses. Cutaneous tumors were induced in CD1 mice using a DMBA/TPA protocol, followed by five weekly intraperitoneal injections of doxorubicin (5 mg/kg). Mice bearing tumors were randomized to receive doxorubicin alone or in combination with weekly RIC (three cycles of 5 min hindlimb ischemia/reperfusion). Longitudinal echocardiography was used to assess cardiac function, while tumor growth, survival, and body weight were monitored throughout the protocol. Doxorubicin treatment reduced overall survival, inhibited tumor growth, and induced left ventricular systolic dysfunction and cardiac atrophy compared with untreated controls. RIC preserved left ventricular ejection fraction, partially attenuated early left ventricular atrophy, and showed a trend towards improved survival, without attenuating the antitumor efficacy of doxorubicin, as tumor suppression remained comparable between treatment groups. These findings demonstrate that RIC preserves cardiac systolic function during anthracycline chemotherapy in tumor-bearing mice without impairing the antitumor efficacy of the drug. The results support RIC as a simple, safe, and low-cost non-pharmacological strategy to mitigate AIC with potential translational relevance for oncology patients.
Repisalud
Publication Artículo de revisión (ReviewArticle)

Cardioprotection strategies for anthracycline cardiotoxicity.

  • Moreno-Arciniegas, Andrea
  • Cádiz, Laura
  • Galán-Arriola, Carlos
  • Clemente-Moragón, Agustín
  • Ibáñez, Borja
Thanks to the fantastic progress in cancer therapy options, there is a growing population of cancer survivors. This success has resulted in a need to focus much effort into improving the quality of life of this population. Cancer and cardiovascular disease share many common risk factors and have an interplay between them, with one condition mechanistically affecting the other and vice versa. Furthermore, widely prescribed cancer therapies have known toxic effects in the cardiovascular system. Anthracyclines are the paradigm of efficacious cancer therapy widely prescribed with a strong cardiotoxic potential. While some cancer therapies cardiovascular toxicities are transient, others are irreversible. There is a growing need to develop cardioprotective therapies that, when used in conjunction with cancer therapies, can prevent cardiovascular toxicity and thus improve long-term quality of life in survivors. The field has three main challenges: (i) identification of the ultimate mechanisms leading to cardiotoxicity to (ii) identify specific therapeutic targets, and (iii) more sensible diagnostic tools to early identify these conditions. In this review we will focus on the cardioprotective strategies tested and under investigation. We will focus this article into anthracycline cardiotoxicity since it is still the agent most widely prescribed, the one with higher toxic effects on the heart, and the most widely studied.
Repisalud
Publication Artículo científico (JournalArticle)

Imidazole propionate is a driver and therapeutic target in atherosclerosis.

  • Mastrangelo, Annalaura
  • Robles-Vera, Iñaki
  • Mañanes, Diego
  • Galán, Miguel
  • Femenía-Muiña, Marcos
  • Redondo-Urzainqui, Ana
  • Barrero-Rodríguez, Rafael
  • Papaioannou, Eleftheria
  • Amores-Iniesta, Joaquín
  • Devesa, Ana
  • Lobo-González, Manuel
  • Carreras, Alba
  • Beck, Katharina R
  • Ivarsson, Sophie
  • Gummesson, Anders
  • Georgiopoulos, Georgios
  • Rodrigo-Tapias, Manuel
  • Martínez-Cano, Sarai
  • Fernández-López, Ivan
  • Nuñez, Vanessa
  • Ferrarini, Alessia
  • Inohara, Naohiro
  • Stamatelopoulos, Kimon
  • Benguría, Alberto
  • Cibrian, Danay
  • Sánchez-Madrid, Francisco
  • Alonso-Herranz, Vanesa
  • Dopazo, Ana
  • Barbas, Coral
  • Vázquez, Jesús
  • López, Juan Antonio
  • González-Martín, Alicia
  • Nuñez, Gabriel
  • Stellos, Konstantinos
  • Bergström, Göran
  • Bäckhed, Fredrik
  • Fuster, Valentín
  • Ibañez, Borja
  • Sancho, David
Atherosclerosis is the main underlying cause of cardiovascular diseases. Its prevention is based on the detection and treatment of traditional cardiovascular risk factors. However, individuals at risk for early vascular disease often remain unidentified. Recent research has identified new molecules in the pathophysiology of atherosclerosis, highlighting the need for alternative disease biomarkers and therapeutic targets to improve early diagnosis and therapy efficacy. Here, we observed that imidazole propionate (ImP), produced by microorganisms, is associated with the extent of atherosclerosis in mice and in two independent human cohorts. Furthermore, ImP administration to atherosclerosis-prone mice fed with chow diet was sufficient to induce atherosclerosis without altering the lipid profile, and was linked to activation of both systemic and local innate and adaptive immunity and inflammation. Specifically, we found that ImP caused atherosclerosis through the imidazoline-1 receptor (I1R, also known as nischarin) in myeloid cells. Blocking this ImP-I1R axis inhibited the development of atherosclerosis induced by ImP or high-cholesterol diet in mice. Identification of the strong association of ImP with active atherosclerosis and the contribution of the ImP-I1R axis to disease progression opens new avenues for improving the early diagnosis and personalized therapy of atherosclerosis.
Repisalud
Publication Artículo científico (JournalArticle)

Pharmacogenomics and chronotherapy of drug-induced cardioprotection in acute myocardial infarction.

  • Clemente-Moragón, Agustín
  • Suárez-Barrientos, Aida
  • Gómez Tech, Mónica
  • López-Palomar Tech, Lucía Pilar
  • Callejas Alejano, Sergio
  • Martínez, Fernando
  • Fernández, Francisco José
  • Vega, María Cristina
  • Tech, Angela Pollán
  • Dopazo, Ana
  • Sánchez-Cabo, Fátima
  • Fuster, Valentín
  • Oliver, Eduardo
  • Ibáñez, Borja
Acute myocardial infarction remains a leading cause of morbidity and mortality worldwide. Pharmacogenetic and chronotherapeutic approaches are increasingly applied to optimize therapy in chronic cardiovascular diseases. While gene variants are known to influence long-term drug efficacy, their role in modulating drug-induced cardioprotection in acute conditions such as myocardial infarction is unclear. Similarly, the impact of circadian timing on cardioprotective responses remains insufficiently defined. To address these questions, we evaluated metoprolol as a model cardioprotective agent. Here we examine, in a non-pre-specified exploratory analysis of the METOCARD-CNIC trial (NCT01311700), the influence of ADRB1 Arg389Gly polymorphism and the time of AMI onset on metoprolol efficacy. We found that metoprolol reduced infarct size only in patients homozygous for the ADRB1 Arg389 allele, consistent with its genotype-dependent inhibition of neutrophil migration. In-silico docking and binding studies revealed unstable interactions of metoprolol with the Gly389 variant of ADRB1. Moreover, metoprolol was associated with reduced infarct size when AMI onset occurred between 6:00 and 12:00 h. Restricted cardioprotection to the light phase was confirmed in male mice and in neutrophil-specific Adrb1-knockout models. Collectively, these findings highlight the critical roles of genetic background and circadian timing in shaping the efficacy of acute cardioprotective therapies, supporting the rationale for personalized interventions in acute myocardial infarction.
Repisalud
Publication Artículo científico (JournalArticle)

β3-Adrenergic receptor overexpression in cardiomyocytes preconditions mitochondria to withstand ischemia-reperfusion injury.

  • Fernández-Tocino, Miguel
  • Pun-Garcia, Andrés
  • Gómez, Mónica
  • Clemente-Moragón, Agustín
  • Oliver, Eduardo
  • Villena-Gutierrez, Rocío
  • Trigo-Anca, Sofía
  • Díaz-Guerra, Anabel
  • Sanz-Rosa, David
  • Prados, Belén
  • Del Campo, Lara
  • Andrés, Vicente
  • Fuster, Valentín
  • de la Pompa, José Luis
  • Cádiz, Laura
  • Ibañez, Borja
β3-Adrenergic receptor (β3AR) agonists have been shown to protect against ischemia-reperfusion injury (IRI). Since β3ARs are present both in cardiomyocytes and in endothelial cells, the cellular compartment responsible for this protection has remained unknown. Using transgenic mice constitutively expressing the human β3AR (hβ3AR) in cardiomyocytes or in the endothelium on a genetic background of null endogenous β3AR expression, we show that only cardiomyocyte expression protects against IRI (45 min ischemia followed by reperfusion over 24 h). Infarct size was also limited after ischemia-reperfusion in mice with cardiomyocyte hβ3AR overexpression on top of endogenous β3AR expression. hβ3AR overexpression in these mice reduced IRI-induced cardiac fibrosis and improved long-term left ventricular systolic function. Cardiomyocyte-specific β3AR overexpression resulted in a baseline remodeling of the mitochondrial network, characterized by upregulated mitochondrial biogenesis and a downregulation of mitochondrial quality control (mitophagy), resulting in elevated numbers of small mitochondria with a depressed capacity for the generation of reactive oxygen species but improved capacity for ATP generation. These processes precondition cardiomyocyte mitochondria to be more resistant to IRI. Upon reperfusion, hearts with hβ3AR overexpression display a restoration in the mitochondrial quality control and a rapid activation of antioxidant responses. Strong protection against IRI was also observed in mice infected with an adeno-associated virus (AAV) encoding hβ3AR under a cardiomyocyte-specific promoter. These results confirm the translational potential of increased cardiomyocyte β3AR expression, achieved either naturally through exercise or artificially through gene therapy approaches, to precondition the cardiomyocyte mitochondrial network to withstand future insults.
Repisalud
Publication Artículo científico (JournalArticle)

A high-fat diet nutritional intervention reprograms cardiac metabolism and improves systolic function in a pig model of heart failure with reduced ejection fraction.

  • Galán-Arriola, Carlos
  • Pérez-Camargo, Daniel
  • Ferrarini, Alessia
  • Mastrangelo, Annalaura
  • Higuero-Verdejo, María Isabel
  • López-Martín, Gonzalo Javier
  • Devesa, Ana
  • Gutiérrez, Rocío Villena
  • Fernández-Tocino, Miguel
  • Díaz-Guerra, Anabel
  • Montero-Cruces, Lourdes
  • Carnero, Manuel
  • Fernández-Jiménez, Rodrigo
  • Fuster, Valentin
  • Sánchez-González, Javier
  • Ibáñez, Borja
Most forms of heart failure are characterized by a metabolic switch from the use of fatty acids to glucose as the main fuel source for ATP generation in the myocardium. Whether metabolic reprogramming is a therapeutic target remains controversial. In this study, heart failure with reduced ejection fraction (HFrEF) and metabolic switch (i.e., increased myocardial glucose uptake) was induced in pigs by generating viable dysfunctional myocardium secondary to progressive coronary artery stenosis. Pigs (n = 19) were then randomized to a high-fat diet (HFD, chow diet supplemented with 20% lard) or control diet (no supplementation) for two months. Pre- and post-nutritional treatment contrast-enhanced cardiac magnetic resonance (CMR) and FDG-PET/CT studies were performed. Hearts were then harvested for further analysis. LVEF significantly improved in pigs receiving the 2-month HFD (38% [33, 43] to 54% [47, 62], p = 0.036) but remained unchanged in control-diet pigs (36% [35, 45] to 41% [38, 43], p = 0.24). HFD-fed pigs had a smaller extent of fibrosis after the dietary intervention (late gadolinium enhancement 0.45% LV [0.17, 1.67] vs 6.23 [5.54, 9.57], p = 0.0047). On FDG-PET, a reversion of the metabolic reprogramming in the LAD-dysfunctional myocardium was observed only in HFD-fed pigs (0.46 counts [0.21, 0.65] vs 1.80 [1.53, 2.83], p = 0.016). Transmission electron microscopy of explanted hearts revealed less fragmented mitochondrial and a lower lipid droplet density in cardiomyocytes from HFD-fed pigs (38 per 10 µm3 [34, 50] vs 96 [78, 124], p = 0.022), and this was accompanied by increased expression of genes involved in fatty acid metabolism and downregulation of genes encoding glucose import proteins. In conclusion, in a large animal model of HFrEF secondary to myocardial dysfunction with a metabolic switch, a nutritional intervention based on HFD feeding was associated with a cardiac metabolic restoration of fatty acid substrate use, restoration of cardiomyocyte lipid trafficking and significantly improved systolic function.